Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Intramuscular Risperidone ISM vs Oral Risperdal in Schizophrenia
NCT05179525Phase 1Completed
- Sponsor
- Laboratorios Farmacéuticos ROVI
- Start
- Mar 2021
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of risperidone in schizophrenia, sponsored by Laboratorios Farmacéuticos ROVI. Primary endpoint: Area under the curve during the dosing interval. Started Mar 2021; status: completed.
02
Drugs
risperidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT05179525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05179525.